期刊简介
1985年创刊，中华医学会主办。本刊是反映我国当代及与国外合作的，在内分泌代谢病学领域内临床与科研最新成果的高级学术刊物。在强调刊文的先进性、科学性与新颖性的同时，也十分重视临床的实用性和论文的可读性。本刊设指南与共识、述评、专论、论坛、临床研究、基础研究、综述、讲座、临诊应对、当年学术进展与动态、临床经验交流、新药研究、学术争鸣及国外期刊论文评论等栏目。本刊的读者对象主要为各级从事临床和基础内分泌代谢病学工作的医、教、研人员及研究生，以及内、外、儿、妇科以及神经、泌尿、老年、营养等相关科室的人员。
往期目录
-
2000
-
2001
-
2002
-
2003
-
2004
-
2005
-
2006
-
2007
-
2008
-
2009
-
2010
-
2011
-
2012
-
2013
-
2014
-
2015
-
2016
-
2017
-
2018
-
2019
首页>中华内分泌代谢杂志
- 杂志名称：中华内分泌代谢杂志
- 主管单位：中国科学技术协会
- 主办单位：中华医学会
- 国际刊号：1000-6699
- 国内刊号：31-1282/R
- 出版周期：月刊
期刊荣誉：92年12月获中华医学会华瑞杯优秀期刊三等奖期刊收录：CA 化学文摘(美), 维普收录(中), 北大核心期刊(中国人文社会科学核心期刊), 万方收录(中), 国家图书馆馆藏, 统计源核心期刊(中国科技论文核心期刊), JST 日本科学技术振兴机构数据库(日), 上海图书馆馆藏, 知网收录(中), CSCD 中国科学引文数据库来源期刊(含扩展版)
The ACE trial:a new perspective on the effect of acarbose on cardiovascular outcomes
Chantal Mathieu
关键词：Acarbose, Pre-diabetes, Cardiovascular
摘要：The Acarbose Cardiovascular Evaluation ( ACE ) trial assessed whether acarbose could reduce the incidence of cardiovascular event ( CVE) s in Chinese patients suffering from impaired glucose tolerance ( IGT) and coronary heart disease. ACE differs from a previous study on IGT people, the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus ( STOP-NIDDM) trial in terms of sample size, number of CVE, mean age, acarbose dose, and population. ACE supported STOP-NIDDM's results by showing that acarbose prevents the progression of prediabetes to diabetes in IGT people, and extended the effect to people with coronary heart disease. However it did not reduce CVE incidence, probably due to the low dose used (50 mg tid). Overall, ACE is well-designed and high-powered enough to confirm that acarbose can prevent progression of prediabetes to diabetes, but is not able to reduce CVE incidence. However, in light of the fast growing prediabetic Chinese population, usage of acarbose is warranted to avert an explosion of diabetes.
友情链接